Friday , December 4 2020

Florencia González Lizárraga is investigating Parkinson's and has received an award



Proud to her work, her team and the level of science that is being done in Tucuman, Florencia González Lizárraga He is grateful for the difference he received from the Argentine Society of Biology, which is the most important type of organization in the country. He won the Jorge Ponce Hornos Award after he was selected among 350 scientists from across the country. "This work is synonymous with a doctoral thesis (she will be a Biological Sciences) I am the first author of the work, but we are discussing these issues as a team ", it's clear.

An investigation was carried out to Florence at the Institute of Medical Medicine and Complex Cells (Immca), which relies on the UNT, the Conicet and the State Health Ministry, which is responsible for Rosana Chehín. The work is also counted on the co-operation of the Advanced UBA Ficroscopy Center, which directs His Pietrasanta. Floren was yesterday when she spoke on the phone with LA GACETA.

The research of the young scientist is an antibiotics of the name dioxycycline, which belongs to the tetracyclines group. This antibiotics has the ability to interact with the Alpha-synuclein protein, which is responsible for the death of dopasinérgicas neurons (those who communicate with other neurons by dopamine). Here are the dead neurons in those who suffer from Parkinson's.

However, doxycycline is not appropriate for long-term diseases such as neuroscience diseases because it can create bacteria resistant.

"The second part of the job is to find a medication of the name COL 3, which is also tetracycline, but has modified genetic so that it does not have any antibiotic activity so it will not create resistance And has anti-inflammatory actions and does not cause the alpha-synuclein protein that is not toxic. As a result, there is no death of dopano-neurons.

"In this way Parkinson's disease stops, that is, it is not palliative treatment, as the current treatments", highlight Florencia.

Of course, the research is still in laboratory period. In vitro and in vivo tests are being done, but there is still a long way of going to a period of clinical trials among people. However, it's definitely the great hope.

The second mention of the Ponce Hornos Prize was also for Tucuman: Luciana Medina, for work on Alzheimer's disease.


Source link